Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

C. N. Sternberg*, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, L. Collette, D. Lacombe, Christine de Balincourt, Steven Deleu, Jérôme Rapion, A. T. Van Oosterom, Th M. de Reijke, M. De Santis, A. Verbaeys, F. RingeisenJ. Bellmunt, P. Albers, F. Calais-da-Silva

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences